menu toggle

Manufacturer Solutions

Landscape of Humira® biosimilars

The biosimilar market has seen a number of new biosimilars launch that reference Humira®, one of the top selling drugs in the world. Since its launch, Humira® has evolved from its original, low concentration (50mg) citrate version to a high concentration (100mg) citrate-free version.  The biosimilars that have launched and are in development in reference to Humira® have differing product attributes from low concentration (50mg) vs high concentration (100mg) and citrate vs citrate free versions. Humira® biosimilars have launched with varying WAC prices, with discounts ranging from 5% up to 86%.

We believe in the promise of biosimilars to deliver cost savings across healthcare. We also understand the potential hurdles these unique products will face. Our guide to biosimilars* that reference Humira® is designed to help providers and patients navigate this changing market.

Launched in the United States

Company Product name   Launch date Interchangeability status Safety Information Concentration  Citrate free  WAC Price
Amgen Amjevita™ Dec 12, 2023   Read more 100MG Yes $1,385.22
Amgen1 Amjevita™ Jan 31, 20231
Read more 50MG2 Yes1 $6,922.62
Amgen1 Amjevita™ Jan 31, 20231
Read more 50MG2 Yes1 $3,115.18
Boehringer Ingelheim22  adalimumab-adbm  October 2, 202322  Approved22  Read more  50MG22  Yes22  $1,315.30 
Boehringer Ingelheim7
Cyltezo®  July 1, 20237  Approved7 Read more  50MG8  Yes7  $6,576.49 
Boehringer Ingelheim adalimumab-adbm May 1, 2024   Read more 100MG Yes $1,315.30
Boehringer Ingelheim Cyltezo®  May 1, 2024   Read more 100MG Yes $6,576.49
Celltrion
Yuflyma  July 1, 2023    Read more  100MG  Yes $6,576.50 
Celltrion Adalimumab-aaty
May 9, 2024   Read more 100MG  Yes $1,038.00
Coherus9  Yusimry™  July 1, 2023 r9    Read more
50MG9  Yes10
$995.00 
Fresenius  Adalimumab-aacf  January 15, 2024    Read more  50MG   Yes  $899.00 
Fresenius Kabi19  Idacio®  July 1, 202319    Read more  50MG21  Yes19  $6,576.49 
Organon4 Hadlima™ July 1, 2023 5
Read more 50MG6 No6 $1,038.00
Organon4 Hadlima™ July 1, 2023 18
Read more 100MG18 Yes18 $1,038.00
Pfizer15
Abrilada™  November 1, 2023  Approved
Read more  50MG17  Yes16  $6,576.49  
Pfizer15
Abrilada™
November 1, 2023  Approved
Read more  50MG17  Yes16
$2,769.05 
Sandoz20  Hyrimoz™ 
July 1, 202320
Approved Read more
100MG20
Yes20
$6,576.49
Sandoz20
adalimumab-adaz
July 1, 202320
Approved
Read more
100MG20
Yes20
$1,038.00
Teva Simlandi May 20, 2024 Approved Read more 100MG Yes $1,038.00
Viatris11 Hulio™ July 1, 202311
Read more 50MG11 Yes12 $6,576.49
Viatris23 adalimumab-fkjp July 1, 202323
Read more 50MG23 Yes23 $995.00

 

*WAC price represents the price for a two pack of pens or pre-filled syringes

*This page is intended to assist health care providers in navigating the complicated biosimilars landscape. It should not be used to make prescribing or treatment decisions. Some therapies on this page may not have been approved by the Food and Drug Administration (FDA) or have been cleared for specific uses only. It is the responsibility of the physician to determine the FDA clearance status of each therapy in clinical practice. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.

15 FDA Approves Pfizer’s Biosimilar, ABRILADA™
16 FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™
17 ABRILADA- adalimumab-afzb 

Updated: 10/06/2023

Additional resources

biosim2

Biosimilar resources for providers

As a provider, you make choices every day about what medications to prescribe or recommend. A biosimilar and its reference product will provide the same clinical results for your patients. We want you to feel confident in your decision to pick biosimilars for your patients.
biosimilar_vials

Biosimilars pipeline report

This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market. 
Biosimilars 101

Manufacturer solutions

We believe in the promise of biosimilars to deliver cost savings across healthcare. We also understand the potential hurdles these unique products will face. That's why we offer solutions for increasing access to and confidence in these emerging therapies.

Connect with our team

We are here to support you with innovative solutions to help increase access to these emerging therapies.